Translational quantitative systems toxicology to improve the understanding of the safety of medicines

A new European research project has been launched which aims to improve the understanding of adverse drug reactions and the approach of systems modelling approaches to drug safety.

Adverse drug reactions (ADRs) are the unwanted side effects of medication. They can contribute significantly to patient morbidity, mortality and hospitalisation costs.

Funded by the Innovative Medicines Initiative 2 Joint Undertaking (IMI 2 Joint Undertaking) the five-year project, called Translational Quantitative Systems Toxicology (TransQST), aims to develop novel computational approaches using the best available data from the public and private domains to address the problems of drug safety.

TransQST is a partnership between ten academic institutions, three Small and Medium-sized enterprises (SMEs) and eight pharmaceutical companies, with a total budget of €16m. The project will be coordinated by the University of Liverpool, and the pharmaceutical company AbbVie is the Project Leader.